title: Undetectable Thyroglobulin Levels in Poorly Differentiated Thyroid Carcinoma Patients Free of Macroscopic Disease After Initial Treatment: Are They Useful?
abstract: BACKGROUND
  Predictive role of undetectable thyroglobulin (Tg) in patients with poorly differentiated thyroid carcinoma (PDTC) is unclear. Our goal was to report on Tg levels following total thyroidectomy and adjuvant RAI in PDTC patients and to correlate Tg levels with recurrence.
  
  
  METHODS
  Forty patients with PDTC with no distant metastases at presentation (M0) and managed by total thyroidectomy and adjuvant RAI were identified from a database of 91 PDTC patients. Of these, 31 patients had Tg values recorded and formed the basis of our analysis. A nonstimulated Tg level <1 ng/ml was used as a cutoff point for undetectable Tg levels. Association of patient and tumor characteristics with Tg levels was examined by χ (2) test. Recurrence-free survival (RFS) stratified by postop Tg level was calculated by Kaplan-Meier method and compared by log-rank test.
  
  
  RESULTS
  Twenty patients had undetectable Tg (<1 ng/ml) and 11 had detectable Tg (≥1 ng/ml; range 2-129 ng/ml) following surgery. After adjuvant RAI, 24 patients had undetectable Tg (<1 ng/ml) and 7 had detectable Tg (≥1 ng/ml; range 1-57 ng/ml). Patients with undetectable Tg were less likely to have pathologically positive margins compared to those with detectable Tg (33 vs. 72 % respectively; p = 0.03). Patients with undetectable Tg levels had better 5-year regional control and distant control than patients with detectable Tg level (5-year regional recurrence-free survival 96 vs. 69 %; p = 0.03; 5-year distant recurrence-free survival 96 vs. 46 %, p = 0.11).
  
  
  CONCLUSIONS
  Postoperative thyroglobulin levels in subset of patients with PDTC appear to have predictive value for recurrence. Patients with undetectable Tg have a low rate of recurrence.
authors.affiliation: Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. tihana_i@yahoo.co.uk.
authors.forename: Tihana
authors.initials: T
authors.lastname: Ibrahimpasic
authors.affiliation: Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ghosseir@mskcc.org.
authors.forename: Ronald
authors.initials: R
authors.lastname: Ghossein
authors.affiliation: Department of Pathology, Cleveland Clinic, Weston, FL, USA. carlsod@ccf.org.
authors.forename: Diane L
authors.initials: DL
authors.lastname: Carlson
authors.affiliation: Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. iainjnixon@gmail.com.
authors.forename: Iain J
authors.initials: IJ
authors.lastname: Nixon
authors.affiliation: Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. fpalmer16@gsb.columbia.edu.
authors.forename: Frank L
authors.initials: FL
authors.lastname: Palmer
authors.affiliation: Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. patels@mskcc.org.
authors.forename: Snehal G
authors.initials: SG
authors.lastname: Patel
authors.affiliation: Department of Endocrinology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. tuttlem@mskcc.org.
authors.forename: Robert M
authors.initials: RM
authors.lastname: Tuttle
authors.affiliation: Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. shahaa@mskcc.org.
authors.forename: Ashok
authors.initials: A
authors.lastname: Shaha
authors.affiliation: Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. shahj@mskcc.org.
authors.forename: Jatin P
authors.initials: JP
authors.lastname: Shah
authors.affiliation: Department of Head and Neck Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. ganlyi@mskcc.org.
authors.forename: Ian
authors.initials: I
authors.lastname: Ganly
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000097:blood* / Q000473:pathology / Q000601:surgery; D014408:Biomarkers, Tumor / Q000097:blood*; D002291:Carcinoma, Papillary / Q000097:blood* / Q000473:pathology / Q000601:surgery; D002454:Cell Differentiation; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D013954:Thyroglobulin / Q000097:blood*; D013964:Thyroid Neoplasms / Q000097:blood* / Q000473:pathology / Q000601:surgery; D013965:Thyroidectomy
chemical_list: D014408:Biomarkers, Tumor; D013954:Thyroglobulin